Surgically implanted devices having reduced scar tissue formation

Overview

Information

Number
6534693
Application
09/772693
Filing date
01/31/2001
Issue date
03/18/2003
Inventor(s)
Robert E. Fischell, David R. Fischell, Tim A. Fischell, Scott J. S. Fischell
US Classification
602/43; 602/48
View at USPTO

Citations

NA (4)
Pfizer (3)
Houston Biotechnology (2)
American National Red Cross (2)
Abbott Laboratories (2)
Novartis (2)
REGENTS OF THE UNIVERSITY OF MICHIGAN, THE (1)
Boston Scientific (1)
HEWITT, CHARLES W. (1)
General Hospital (1)
Chitogenics (1)
Alcon Manufacturing, (1)
ALABAMA AT BIRMINGHAM, UNIVERSITY OF (1)
University of Louisville Research Foundation (1)
Genzyme (1)
NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (1)
BLACK, KIRBY S. (1)
Colla-Gene (1)
C.R. Bard (1)
President And Fellows Of Harvard College (1)
Coalition for Hemophilia B (1)
Trustees of Boston University (1)
Arch Development (1)
tin dba temple inland (1)

Abstract

Abstract

This invention is an anti-proliferative drug placed onto or within a sterile sheet or mesh that is designed to be placed between internal body tissues to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. This mesh or gauze onto or into which the drug is placed may be either a permanent implant or it may be biodegradable. By impregnating an existing product such as the Johnson & Johnson SURGICEL.TM. absorbable hemostat gauze-like sheet with an anti-proliferative drug such as Rapamycin or Taxol, the biodegradable, drug impregnated mesh would act as a barrier to cell proliferation and hence be a deterrent to the formation of adhesions. Another embodiment of this invention is an anti-proliferative drug attached to a bandage that is placed onto a cut in the skin to decrease scar tissue formation. Still another embodiment of the invention is an anti-proliferative drug that is attached to a surgical suture or coated onto a surgical staple both of which are used for connecting human tissues. The suture or staple then being more capable for decreasing cellular proliferation where the suture or staple material passes through the human tissue.

Assignees with Similar Patents

Referenced by

Atrium Medical (40)
Cyberonics (33)
Santen Pharmaceutical Co. (12)
MATI THERAPEUTICS INC. (9)
xcede technology (7)
livanova usa (5)
Vascular Therapies, (4)
PEYMAN, GHOLAM A., DR. (4)
Kensey Nash (4)
optivue l l p (2)
Massachusetts Eye & Ear Infirmary (2)
The Trustees of The University Of Pennsylvania (2)
DSM IP Assets B.V. (2)
MINU, L.L.C. (2)
Oregon Health & Science University (2)
DiLorenzo Biomedical, (1)
Postech Academy-Industry Foundation (1)
Covidien (1)
GT Urological, (1)
isos solutions (1)
QLT (1)
Shin Poong Pharmaceutical Co. (1)
Endovascular Devices (1)

Tech Analysis

Class Subclass Type Reference Factor Citation Factor Strength Grant time Early grant (%)
602 43 Stable Average Seminal Medium Average 33.3
602 48 Stable Sustaining Seminal Medium Average 35.2